

# Consolidated Financial Results for the Fiscal Year Ended February 28, 2018 [Japanese GAAP]



April 13, 2018

Company name: Kirindo Holdings Co., Ltd.  
 Stock exchange listing: Tokyo Stock Exchange  
 Code number: 3194  
 URL: <http://www.kirindo-hd.co.jp>  
 Representative: Toyohiko Teranishi, Chief Executive Officer, President  
 Contact: Takehisa Kobayashi, Corporate Officer, Corporate Planning Department  
 Phone: +81-6-6394-0100  
 Scheduled date of Annual General Meeting of Shareholders: May 25, 2018  
 Scheduled date of filing annual securities report: May 28, 2018  
 Scheduled date of commencing dividend payments: May 10, 2018  
 Availability of supplementary briefing material on annual financial results: Available  
 Schedule of annual financial results briefing session: Scheduled (for securities analysts and institutional investors)

(Amounts of less than one million yen are rounded down.)

## 1. Consolidated Financial Results for the Fiscal Year Ended February 28, 2018 (March 1, 2017 to February 28, 2018)

(1) Consolidated Operating Results (% indicates changes from the previous corresponding period.)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Fiscal year ended February 28, 2018	126,666	8.8	1,937	49.2	2,604	41.9	1,291	103.4
February 28, 2017	116,450	3.1	1,298	(23.6)	1,835	(20.9)	635	(23.2)

(Note) Comprehensive income: Fiscal year ended February 28, 2018: ¥1,286 million [121.9 %]

Fiscal year ended February 28, 2017: ¥579 million [(20.7) %]

	Basic earnings per share	Diluted earnings per share	Rate of return on equity	Ordinary income to total assets	Operating income to net sales
	Yen	Yen	%	%	%
Fiscal year ended February 28, 2018	116.45	-	9.8	5.5	1.5
February 28, 2017	56.46	-	5.1	4.0	1.1

(Reference) Equity in earnings (losses) of affiliated companies: Fiscal Year ended February 28, 2018: ¥- million

Fiscal Year ended February 28, 2017: ¥- million

## (2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of February 28, 2018	49,380	13,767	27.8	1,232.85
As of February 28, 2017	46,054	12,667	27.4	1,142.96

(Reference) Equity: As of February 28, 2018: ¥13,734 million

As of February 28, 2017: ¥12,616 million

## (3) Consolidated Cash Flows

	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalents at end of period
	Million yen	Million yen	Million yen	Million yen
Fiscal year ended February 28, 2018	3,585	(2,764)	408	8,564
February 28, 2017	2,357	(2,533)	329	7,335

## 2. Dividends

	Annual dividends					Total dividends	Payout ratio (consolidated)	Dividends to net assets (consolidated)
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total			
Fiscal year ended	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
February 28, 2017	-	12.50	-	12.50	25.00	283	44.3	2.2
February 28, 2018	-	12.50	-	17.50	30.00	339	25.8	2.5
Fiscal year ending February 28, 2019 (Forecast)	-	17.50	-	17.50	35.00		26.8	

## 3. Consolidated Financial Results Forecast for the Fiscal Year Ending February 28, 2019 (March 1, 2018 to February 28, 2019)

(% indicates changes from the previous corresponding period.)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	66,300	4.2	960	24.9	1,280	11.5	560	(12.1)	50.18
Full year	131,500	3.8	2,580	33.2	3,240	24.4	1,460	13.0	130.54

### \* Notes:

- (1) Changes in significant subsidiaries during the period under review (changes in specified subsidiaries resulting in changes in scope of consolidation): Yes  
 Newly included: One (Company name: MEDICINE SHOPPE JAPAN, K.K.)  
 Excluded: - (Company name: )  
 (Note) MEDICINE SHOPPE JAPAN, K.K. ceased to be a specified subsidiary during the period.
- (2) Changes in accounting policies, changes in accounting estimates and retrospective restatement
  - 1) Changes in accounting policies due to the revision of accounting standards: Yes
  - 2) Changes in accounting policies other than 1) above: No
  - 3) Changes in accounting estimates: No
  - 4) Retrospective restatement: No
 (Note) Please refer to “3. Consolidated Financial Statements (5) Notes to Consolidated Financial Statements (Changes in accounting policies)” on page 15 of the Consolidated Financial Results (attached material) for details.
- (3) Total number of issued shares (common shares)
  - 1) Total number of issued shares at the end of the period (including treasury shares):  
 February 28, 2018: 11,332,206 shares  
 February 28, 2017: 11,332,206 shares
  - 2) Total number of treasury shares at the end of the period:  
 February 28, 2018: 192,157 shares  
 February 28, 2017: 293,457 shares
  - 3) Average number of shares during the period:  
 Fiscal year ended February 28, 2018: 11,094,314 shares  
 Fiscal year ended February 28, 2017: 11,248,116 shares
 (Note) For the number of shares used as the basis for calculating basic earnings per share (consolidated), please refer to “3. Consolidated Financial Statements (5) Notes to Consolidated Financial Statements (Per share information)” on page 25 of the Consolidated Financial Results (attached material).

\* These financial results are outside the scope of audit by a certified public accountant or an audit firm.

\* Explanation of the proper use of financial results forecasts and other notes

The financial results forecasts and other forward-looking statements in this document are based on information currently available and certain assumptions the Company deems to be reasonable. Actual results may differ significantly from these forecasts due to a wide range of factors. Please refer to “1. Overview of Operating Results (4) Future Outlook” on page 3 of the Consolidated Financial Results (attached material) for assumptions for financial results forecasts and notes to the use of financial results forecasts.